Madrigal Pharmaceuticals, Inc. · NASDAQ:MDGL
Madrigal Pharmaceuticals — Investor Presentation (January 2024)
11 slides from Madrigal Pharmaceuticals's investor presentation, Jan 8, 2024
Slide 1: Corporate Presentation January 2024
Corporate Presentation January 2024 Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429, NCT04197479, NCT05500222). Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Madrigal Pharmaceuticals This presentation includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal’s beliefs and assumptions and on information currently available
Slide 3: The Madrigal Opportunity
The Madrigal Opportunity Building the Leading Biopharmaceutical Company in NASH Madrigal Pharmaceuticals NASH is a disease with significant unmet need, and no approved therapies Unprecedented Phase 3 results - first therapy to achieve NASH resolution and fibrosis improvement primary endpoints First-
Slide 4: Taking on a Serious Liver Disease
Taking on a Serious Liver Disease NASH with Significant Fibrosis Carries a High Burden for Patients Madrigal Pharmaceuticals NASH increases risk of cirrhosis, liver failure, liver cancer, and premature mortality Risk of liver-related mortality increases substantially once significant fibrosis develo
Slide 5: Focusing on Patients Who are Most in Need
Focusing on Patients Who are Most in Need Specialty Launch Will Focus on Patients With Significant Fibrosis (Consistent with F2/F3) Seen by Heps/GIs Madrigal Pharmaceuticals U.S. NASH Waterfall at Launch1 Number of Patients 1. Forian Claims Data; Clearview Analysis; Fishman J, et al. Poster presente
Slide 6: A Liver-directed Oral Therapy
A Liver-directed Oral Therapy Resmetirom to Become the FIRST Foundational Therapy for NASH with Significant Fibrosis Madrigal Pharmaceuticals 1. Institute for Clinical and Economic Review (ICER). Final Evidence Report and Meeting Summary. Last accessed December 4, 2023. Compelling Product Profile Li
Slide 7: Resmetirom Position in the NASH Treatment Paradigm
Resmetirom Position in the NASH Treatment Paradigm Significant Opportunity for Resmetirom Where Unmet Need is Highest Madrigal Pharmaceuticals 1. Estes C, et al. Hepatology. 2018 Jan;67(1):123-133. Potential Treatment Lifestyle change, GLP-1 Resmetirom (MAESTRO-NASH) OUTCOMES trial in F4C Fibrosis S
Slide 8: The MAESTRO Phase 3 Program
The MAESTRO Phase 3 Program The Most Advanced and Comprehensive Clinical Development Program in NASH Madrigal Pharmaceuticals MAESTRO-NAFLD-1 Safety MAESTRO-NASH Significant Fibrosis MAESTRO-NASH OUTCOMES Compensated Cirrhosis Evaluates NASH resolution and/or fibrosis improvement on liver biopsy and
Slide 9: The Pivotal Phase 3 MAESTRO-NASH Trial
The Pivotal Phase 3 MAESTRO-NASH Trial FIRST Phase 3 Trial to Achieve NASH Resolution and Fibrosis Improvement Primary Endpoints Madrigal Pharmaceuticals 1. NASH Resolution (ballooning score=0, inflammation score=0/1, & ≥2-point reduction in NAFLD Activity Score (NAS)) with no worsening of fibrosis;
Slide 10: MAESTRO-NASH Favorable Emerging Safety and Tolerability Profile
The Pivotal Phase 3 MAESTRO-NASH Trial Favorable Emerging Safety and Tolerability Profile Madrigal Pharmaceuticals n (%) Resmetirom 80mg (n=322) Resmetirom 100mg (n=323) Placebo (n=321) ≥1 TEAEs 296 (91.9) 296 (91.6) 269 (92.2) Grade 1 (mild) 71 (22.0) 65 (20.1) 77 (24.0) Grade 2 (moderate) 180 (55.
Slide 11: Building for the Future
Building for the Future First-to-Market Advantage Provides a Long-Term NASH Leadership Opportunity Madrigal Pharmaceuticals Build Organization Hire, train and deploy teams Develop Market Educate stakeholders, establish path from Dx to Rx fulfillment, secure market access Execute Specialty Launch Tar
Madrigal Pharmaceuticals — Investor Presentation (January 2024) on 6ix